MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Wearing-off fluctuations"

  • 2022 International Congress

    SAFINAMIDE: REAL LIFE STUDY. EFFICACY IN SWITCH FROM RASAGILINA AND LOW-DOSE TREATMENT.

    MI. Morales-Casado, N. López-Ariztegui, DD. García-Meléndez, A. Diezma-Martín (Toledo, Spain)

    Objective: Evaluate the efficacy of safinamide in fluctuations in Parkinson's disease in real life. Analysis by subgroups: Switch rasagiline to safinamide and treatment with low…
  • 2022 International Congress

    Clinical Outcomes and Disease Burden of Advanced Parkinson’s Disease Patients Treated with Oral Medication Vs. Device-Aided Therapies: Preliminary Results from the University of Florida Registry Analysis

    W. Hu, O. Ladhani, P. Kukreja, A. Ramirez-Zamora (Gainesville, USA)

    Objective: Compare real-world clinical outcomes of Parkinson’s disease (PD) patients with moderate/severe motor fluctuations and/or dyskinesia treated with oral medications compared to device-aided therapies. Background:…
  • 2022 International Congress

    Exploring the morning akinesia in Parkinson’s disease with the wearable sensor STAT-ON

    N. Caballol, C. Pérez-López, A. Pérez-Soriano, A. Planas-Ballvé, A. ávila, P. Quispe, A. Bayés (Sant Joan Despí, Spain)

    Objective: To detect the morning akinesia (MA) through the analysis of the gait fluidity (GF) measured by the sensor STAT-ON. Background: The STAT-ON sensor's detection…
  • 2022 International Congress

    Duration of continuous “Good On” intervals and number of motor fluctuations after treatment with IPX203 vs immediate-release carbidopa-levodopa in Parkinson’s disease patients with motor fluctuations.

    R. Hauser, H. Fernandez, J. Aldred, C. Singer, H. Shill, S. Factor, H. Visser, R. D'Souza (Tampa, USA)

    Objective: To compare the duration of continuous “On” without troublesome dyskinesia (“Good On”) intervals and number of motor fluctuations per day in Parkinson’s disease (PD)…
  • 2022 International Congress

    Gait analysis using Wearable Sensors: different gait metrics can differentiate Parkinson’s Disease Patients from Healthy Controls and Parkinson’s Disease patients in different medication status

    R. Barbosa, M. Medonça, R. Oliveira, M. Santos, A. Abreu, P. Bastos, P. Pita-Lobo, A. Valadas, L. Correia-Guedes, J. Ferreira, M. Rosa, R. Matias, M. Coelho (Lisbon, Portugal)

    Objective: To identify which gait metrics better distinguish PD-OFF from PD Best-ON and PD from HC, using a dimensionality-reduction method Background: Objective gait analysis using…
  • 2022 International Congress

    The REONPARK (REgistry of the use of COMT-inhibitors in the maNagement of patients with PARKinson’s disease in Spain who present early motor fluctuations) study: rationale and design of a national, multicentre and prospective study

    L. Lopez-Manzanares, E. Casas-Peña, I. Muro-Garcia, I. Caballero, F. Almeida, I. Tegel, P. Sarasa (Madrid, Spain)

    Objective: To describe the real-world use of catechol-O-methyltransferase (COMT) inhibitors add on to levodopa/dopa decarboxylase inhibitor (DDCI) in patients with Parkinson’s disease (PD) suffering from…
  • 2022 International Congress

    Wearing-off Questionnaire as a quantify measure of Wearing-off

    CE. Mantese, M. Medeiros, A. Schumacher-Schuh, CR. Rieder (Porto Alegre, Brazil)

    Objective: To aim for the correlation of 19- items Wearing Off Questionnaire (WOQ-19) positive items and MDS-UPDRS IV. Background: Parkinson's disease (PD) has a well…
  • 2022 International Congress

    Parkinson’s patient insights, knowledge and experience of treatment – results from a multicountry survey

    F. de Renzis, L. Graham, M. Meinders (Orpington, United Kingdom)

    Objective: To understand the perceptions and knowledge that people with Parkinson’s disease (PD) have about their treatment, available options for advanced PD, and to determine…
  • 2022 International Congress

    The effect of rasagiline on nocturnal hypokinesia: the analysis of the Nocturnal Hypokinesia Questionnaire (NHQ)

    J. Sringean, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To identify the effect of rasagiline on nocturnal hypokinesia based on Nocturnal Hypokinesia Questionnaire (NHQ). Background: Nocturnal hypokinesia refers to the difficulty or the…
  • 2022 International Congress

    Rapid onset of good ON time and improvement in motor-state stability in aPD patients after treatment with continuous subcutaneous foslevodopa/foscarbidopa

    R. Pahwa, M. Soileau, D. Standaert, V. Fung, T. Kimber, I. Malaty, A. Merola, A. Epstein, C. Yan, A. Alobaidi, A. Shewale, N. Fisseha, A. Jeong, M. Facheris, P. Kukreja, J. Zamudio, J. Aldred (Kansas City, USA)

    Objective: To evaluate time to ON without troublesome dyskinesia (‘good ON’) and patterns of motor-state stability throughout the day in patients with advanced Parkinson’s disease…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 26
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley